The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysisCOVID-19 환자의 이버멕틴 사용과 사망률 사이의 연관성: 메타 분석Meta-Analysis Published on 2021-10-012022-09-11 Journal: Pharmacological Reports [Category] SARS, 임상, [키워드] 95% confidence interval Analysis association benefit bias clinical clinical evidence clinical trial control group Controlled controlled trials coronavirus disease Coronavirus disease 2019 COVID-19 database Evidence Google Scholar heterogeneity high risk Hypothesis indicated investigated Ivermectin Meta-analysis Mortality no significant difference Novel coronavirus novel coronavirus disease Odds ratio Patient patients randomized patients with COVID-19 Randomized Randomized controlled trial Randomized controlled trials randomized trials receive Repository risk risk of bia Sample size searched trials Version were used [DOI] 10.1007/s43440-021-00245-z PMC 바로가기 [Article Type] Meta-Analysis
Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled studyCOVID-19 치료에서 이버멕틴의 효능을 평가하는 임상 연구: 무작위 대조 연구Randomized Controlled Trial Published on 2021-10-012022-09-11 Journal: Journal of medical virology [Category] SARS, 임상, 치료제, [키워드] Chloroquine clinical control group coronavirus disease Coronavirus disease 2019 COVID-19 death rate Efficacy Endpoint evaluate group Hospital stay Hospitalized individual infected patients Ivermectin ivermectin dose ivermectin group mechanical ventilation Mild mild to moderate Moderate COVID-19 Mortality no statistically significant difference once daily Open-label outcome Patient patients with COVID-19 Prevent protocol Randomized randomized controlled study receive reducing required significant difference standard care Standard of care statistically significant statistically significant difference treat Treatment two group two groups [DOI] 10.1002/jmv.27122 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials심각한 및 비 종교 CovID-19 환자를 치료하기위한 현재 약물의 효능 및 안전성 : 무작위 위약 대조 시험의 업데이트 된 네트워크 메타 분석Meta-Analysis Published on 2021-09-302022-08-31 Journal: Aging (Albany NY) [Category] meta-analysis, SARS, 진단, [키워드] 95% CI 95% confidence interval all-cause mortality Analysis article bamlanivimab Baricitinib Characteristics clinical coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 patient COVID-19 patients database databases decrease dosage drug duration of follow-up effective Efficacy Efficacy and safety estimates Imatinib Immunoglobulin inception increase in Infection interquartile range Intervention investigated Ivermectin median medication medications monoclonal antibodies monoclonal antibody Network meta-analysis non-severe patient Odds ratio Older Patient patients patients with COVID-19 Placebo proxalutamide question raised randomized placebo-controlled trial randomized placebo-controlled trials Safety Sample size searched secure severe and non-severe patients severe COVID-19 patient severe COVID-19 patients Sotrovimab statistical Treatment treatment-emergent adverse events Trial Variation virological cure was related were used with COVID-19 [DOI] 10.18632/aging.203522 PMC 바로가기 [Article Type] Meta-Analysis
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled TrialsCOVID-19 치료의 효능 : 무작위 대조 시험의 베이지안 네트워크 메타 분석Meta-Analysis Published on 2021-09-282022-08-31 Journal: Frontiers in Public Health [Category] meta-analysis, SARS, 임상, [키워드] Baricitinib Bayesian Clinical efficacy Colchicine colony stimulating factor comprehensive evaluation conducted Controlled Controlled trial convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 treatment COVID-19 treatments death demographic characteristics Dexamethasone discharge discharge rate doxycycline Effect effect size effect sizes Efficacy eligible Endpoint endpoints fixed granulocyte Hierarchical hospital discharge hospital discharge rate Hydroxychloroquine Imatinib Immunoglobulin immunostimulant Immunosuppressant immunosuppressants indicated information interval Intravenous immunoglobulin Ivermectin lower risk measure mechanical ventilation Mortality network Network meta-analysis nitazoxanide Occurrence Odds ratio outcome outcome measures Patient patients peer-reviewed potential COVID-19 treatments provide provided proxalutamide Randomized controlled trials reduce Remdesivir risk sarilumab searched Standard of care Tocilizumab Tofacitinib Treatment Viral viral clearance was used were used WHO [DOI] 10.3389/fpubh.2021.729559 PMC 바로가기 [Article Type] Meta-Analysis
Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysisCovid-19의 치료에서 Ivermectin의 효과 및 안전성 : 체계적인 검토 및 메타 분석을위한 프로토콜Article Published on 2021-09-172022-08-31 Journal: BMJ Open [Category] meta-analysis, SARS, 임상, [키워드] acute respiratory syndrome Admission antiviral properties antiviral property approval assessment Bia bias risk carried clinical clinical pharmacology clinical trial clinical trials Clinical use COVID-19 criteria database development Diagnosis drug Effectiveness eligibility Ethical approval Ethics Evidence extracorporeal membrane oxygenation for inclusion Frequency GRADE hospitalisation in some incidence include Infection Infectious diseases intensive care intensive care unit Invasive mechanical ventilation involved item Ivermectin mean difference Meta-analysis methodology Mortality observational studies observational study outcome outcomes Patient patients with COVID-19 PCR-negative peer-reviewed Placebo Prophylactic PROSPERO protocol public health random-effects model randomised clinical trial Randomised clinical trials Real-time PCR registration number registry Relative risk Reporting required respiratory review risk serology test Severe acute respiratory syndrome Side effects subgroup analysis Support Symptom symptom resolution Symptomatic treatment systematic review systematic reviews the mean Treatment Trial Viral Viral load [DOI] 10.1136/bmjopen-2021-050532 PMC 바로가기 [Article Type] Article
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-AnalysisSystematic Review Published on 2021-09-082022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] 95% CIs 95% confidence interval Admission adverse event Analysis baseline benefit CIs Clinical efficacy clinical trial registry Control control group COVID-19 decreased mortality Disease progression Evidence fine-tune Guidance include indicated indication intensive care Ivermectin likelihood mechanical ventilation Meta-analysis methodology Mild moderate disease Mortality negative RT-PCR no difference outcome Participants Patient patients Potential treatment Prophylaxis RCT recipient reported Repository review risk Risk of bias SARS-CoV-2 searched severe disease severe pneumonia significantly subjects Support systematic review Treatment treatment for COVID-19 Treatment protocol was used [DOI] 10.3390/diagnostics11091645 PMC 바로가기 [Article Type] Systematic Review
Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokineticsArticle Published on 2021-09-082022-10-04 Journal: Scientific Reports [Category] SARS, 치료제, [키워드] Affect Apical basolateral basolateral membrane blood stream Cell Biology clearance co-morbidities Compound Concentration COVID-19 dependent on Diseases drug candidate Drug discovery examined expel Favipiravir had no hepatocytes human liver in vitro inhibited inhibiting inhibitory Interaction Ivermectin liver Lopinavir membrane metabolism promote Remdesivir reported Repurposed drug Ritonavir significant effect Toxicity transporter treat Treatment venous viral disease xenobiotics [DOI] 10.1038/s41598-021-97160-3 PMC 바로가기 [Article Type] Article
Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial중년의 중등도 증상 환자에서 아연과 시너지 효과를 나타내는 피하 이버멕틴의 항-COVID 특성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-09-062022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 30-Day mortality absence activities approved Arm blinded calculated Chest clinic clinical co-morbidities co-morbidity comparator coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom Data collection death dissemination doctor ECMO Effectiveness element Endpoint enrolment Evidence evidence of excluded FIVE GRADE Grade 1 grade 3 Grade 5 group groups high resolution high resolution CT high-flow oxygen therapy Hospitalized HRCT Infection institutional review board Intention Invasive mechanical ventilation Ivermectin lung lobe mechanical ventilation morbidities nasal no evidence of noninvasive normal saline number objective outcome outcome assessor outcome assessors oxygen Oxygen therapy oxygen) Pakistan participant Patient patient recruitment patients with moderate PCR Physicians Placebo placebo group placebo-controlled positive pregnant women presence or absence primary care primary endpoints protocol radiological improvement randomisation randomised randomised controlled trial Randomized randomized clinical trial Randomly receive recorded Registered reported requiring supplemental oxygen Sample size SARS-CoV-2 SARS-CoV-2 clearance secondary endpoint seven-point scale severe respiratory syndrome severity Standard standard care status Study protocol Subcutaneous Ivermectin supplemental oxygen supplementary material symptomatic synergy Trial website Zinc [DOI] 10.1186/s13063-021-05487-z PMC 바로가기 [Article Type] Letter
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patientsResearch article Published on 2021-09-012022-10-05 Journal: New Microbes and New Infections [Category] 신약개발, 임상, 치료기술, [키워드] age Analysis antiandrogen approach article baseline clinical equipoise Clinical outcome Combination Comorbidity confirmed case Control control groups COVID-19 death demonstrated disease disease severity drug combination dutasteride early-stage COVID-19 employment enrolled ethical concern FIVE group groups Hospitalization hospitalizations Hydroxychloroquine improvement in viral Ivermectin manifestation mechanical ventilation nitazoxanide outcome Patient pharmacological Placebo positive result precluded prevented prospective observational study proxalutamide raised randomized clinical trial RCTs reduction Respiratory complications safety profile SARS-CoV-2 Sex significantly spironolactone tested therapy untreated patient untreated patients [DOI] 10.1016/j.nmni.2021.100915 [Article Type] Research article
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19Review article Published on 2021-09-012022-10-05 Journal: New Microbes and New Infections [Category] 신약개발, [키워드] animal models Betacoronavirus Committee competitive binding controls correlated COVID-19 death Diseases distribution Efficacy H. pylori indicated Infectious disease Ivermectin mechanism Medicine Meta-analysis morbidity Mortality Mutant strains notable Physiology randomized clinical trial RCT RCTs reduction reductions in risk SARS-CoV-2 SARS-CoV-2 spike protein Seven Sharp Spike protein Treatment tropical yielding [DOI] 10.1016/j.nmni.2021.100924 [Article Type] Review article